Navigation Links
NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
Date:2/27/2008

NEW YORK, February 27 /PRNewswire-FirstCall/ -- NexGen Biofuels Ltd. (f/k/a Healthcare Technologies Ltd.) (the "Company") announced today that on February 26, 2008, the Company received a letter from the Nasdaq Listing Qualification Panel, informing the Company that the Panel had determined to delist the Company's ordinary shares from The Nasdaq Stock Market following a determination by the Staff of the Nasdaq Listing Qualifications Department that the Company had failed to meet the Nasdaq listing standards for a reverse merger in connection with the Company's Plan of Arrangement with NexGen Biofuels Inc. Nasdaq will suspend trading of the Company's ordinary shares effective at the open of business on Thursday, February 28, 2008.

The Company believes that, following the recent filing of a Form 211 by a market maker, its ordinary shares will be eligible for trading on the OTC Bulletin Board.

For more information on NexGen Biofuels, Inc., visit http://www.nexgenbiofuels.net.

Safe harbor: This press release contains certain forward looking statements within the meaning of section 27a of the securities act of 1933 and section 21e of the securities exchange act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement made by or on behalf of healthcare technologies ltd. Readers are referred to the documents filed by the company with the securities and exchange commission, specifically the form 8-k/a filed on February 12, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

Contact: Eran Rotem CFO, +972-3-9277232


'/>"/>
SOURCE NexGen Biofuels Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
2. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
3. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
6. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
8. Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
9. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web
10. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
11. HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... and development (R&D), today announced the launch of Data Science Services ... the rapidly evolving field of precision medicine. , Data Science Services ...
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
Breaking Biology Technology:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... Safety, HealthCare, and Finance sectors announced today that Leaders in Community ... and deploy a community-based supportive services program to reduce recidivism in ... expanding its presence in the state. ... This new program, which is expected to commence ...
(Date:12/16/2016)... 16, 2016   IdentyTechSolutions America LLC , ... and solutions and a cutting-edge manufacturer of software ... is offering seamless, integrated solutions that comprise IDT ... The solutions provide IdentyTech,s customers with combined physical ... from crime and theft. "We are ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
Breaking Biology News(10 mins):